Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer

Inclusion Criteria: * Age 18 years or older * Histologically confirmed and documented recurrent ovarian, fallopian tube, and peritoneal cancer. * Platinum resistant disease, defined as progression within ≤ 6 months from completion of most recent regimen and calculated from the date of the last administered dose of platinum therapy * Must have available archived tumor tissue OR if archived tissue is not available, willing to provide a fresh tumor biopsy * Must have radiologic imaging with a computerized tomography (CT) scan or magnetic resonance imaging (MRI) within 4 weeks of first dose of study drug * Received at least 1 but not more than 3 therapy regimens, not including maintenance or adjuvant therapy * Must have ovarian cancer that is measurable according to RECIST 1.1 * ECOG performance status of 0-1 * Normal gastrointestinal (GI), bone marrow, liver and kidney function * At least 28 days between termination of prior anti-cancer or hormonal therapy and administration of AVB-S6-500 Exclusion Criteria: * Primary platinum-refractory disease (defined as progression during the first platinum regimen or within 4 weeks of completion of the first platinum regimen) * Currently being treated with concurrent anti-cancer therapy or any other interventional treatment or trial * Received prior therapy with Pac or PLD in the recurrent setting, depending on physician-chosen chemotherapy for this study * Significant cardiac disease history * Has other prior or concurrent malignancy within the past 5 years except adequately treated basal cell skin cancer or carcinoma in situ of the cervix * Symptomatic CNS metastasis or metastases * Serious active infection requiring IV antibiotics and/or hospitalization at study entry * Has known previous or current human immune deficiency (HIV) syndrome, hepatitis B, or hepatitis C * Has had paracentesis for ascites within 3 months